Novel acute therapies in the treatment of migraine: impact of re-dosing on cost-utility outcomes

J Med Econ. 2021 Jan-Dec;24(1):512-513. doi: 10.1080/13696998.2021.1915600.
No abstract available

Publication types

  • Letter

MeSH terms

  • Cost-Benefit Analysis
  • Humans
  • Migraine Disorders* / drug therapy